• Donate
  • Contact
Canadian Association of Pompe
  • Home
  • About Us
    • Portraits of Pompe
    • Our Partners
    • Newsletter
  • About Pompe
    • Talk Pompe
    • Webinars
  • Blog
  • Links
  • Connections
Select Page
FDA approves Nexviazyme® (avalglucosidase alfa-ngpt)

FDA approves Nexviazyme® (avalglucosidase alfa-ngpt)

by CAP | Aug 12, 2021 | News

In a recent announcement, the Pompe disease community learned that the U.S. Food and Drug Administration (FDA) has approved Nexviazyme® for the treatment of late-onset Pompe patients that are one year old and older.

Amicus Therapeutics Has Begun the FDA Submission for Their Pompe Drug, AT-GAA

Amicus Therapeutics Has Begun the FDA Submission for Their Pompe Drug, AT-GAA

by CAP | Dec 3, 2020 | News

Amicus Therapeutics has announced they have begun a rolling Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for their drug combination, AT-GAA, to treat late onset Pompe disease (LOPD).

Recent Posts

  • International Pompe Day 2022
  • Julie
  • Brad
  • Rare Disease Day 2022
  • Maze Therapeutics Starting Phase I Clinical Trial with MZE001, A Substrate Reduction Therapy
  • Terms
  • Privacy

Copyright © 2006 - 2023 Canadian Association of Pompe